These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30909323)

  • 1. The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017.
    Kurtz SP; Buttram ME; Margolin ZR; Wogenstahl K
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):700-706. PubMed ID: 30909323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings.
    Buttram ME; Kurtz SP; Dart RC; Margolin ZR
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1083-1086. PubMed ID: 28493425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversion and Illicit Sale of Extended Release Tapentadol in the United States.
    Dart RC; Surratt HL; Le Lait MC; Stivers Y; Bebarta VS; Freifeld CC; Brownstein JS; Burke JJ; Kurtz SP; Dasgupta N
    Pain Med; 2016 Aug; 17(8):1490-6. PubMed ID: 26814267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reductions in prescription opioid diversion following recent legislative interventions in Florida.
    Surratt HL; O'Grady C; Kurtz SP; Stivers Y; Cicero TJ; Dart RC; Chen M
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):314-20. PubMed ID: 24677496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in opioid analgesic abuse and mortality in the United States.
    Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
    N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing rates of buprenorphine diversion in the United States, 2002 to 2019.
    Buttram ME; Kurtz SP; Margolin ZR; Severtson SG
    Pharmacoepidemiol Drug Saf; 2021 Nov; 30(11):1514-1519. PubMed ID: 34302707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
    Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
    PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prescription drug monitoring programs in the United States of America].
    El Burai Félix S; Mack K
    Rev Panam Salud Publica; 2014 Oct; 36(4):270-6. PubMed ID: 25563153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The global diversion of pharmaceutical drugs
non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures.
    Fischer B; Bibby M; Bouchard M
    Addiction; 2010 Dec; 105(12):2062-70. PubMed ID: 20840172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use.
    Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC
    JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse and diversion of buprenorphine sublingual tablets and film.
    Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
    J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions.
    Deyo RA; Irvine JM; Millet LM; Beran T; O'Kane N; Wright DA; McCarty D
    Health Aff (Millwood); 2013 Mar; 32(3):603-13. PubMed ID: 23406570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gabapentin misuse, abuse and diversion: a systematic review.
    Smith RV; Havens JR; Walsh SL
    Addiction; 2016 Jul; 111(7):1160-74. PubMed ID: 27265421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
    Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
    J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the abuse of tapentadol immediate release: the first 24 months.
    Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
    J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.